Table 4.
Domain of RQLQ scores | ICX72 (N = 20) |
Placebo (N = 22) |
||||
---|---|---|---|---|---|---|
Baseline | Change: baseline-end | % Rel change | Baseline | Change: baseline-end | % Rel change | |
Activities | 3.1 (0.3) | 1.3 (0.4) | 41% | 4.1 (0.2) | 1.0 (0.4) | 21% |
Sleep | 2.4 (0.3) | 1.0 (0.3) | 43% | 3.2 (0.3) | 0.6 (0.3) | 18% |
Non-nasal/eye symptoms | 2.4 (0.3) | 1.1 (0.3) | 45% | 3.3 (0.2) | 0.7 (0.3) | 21% |
Practical problems | 2.3 (0.3) | 1.0 (0.3) | 43% | 3.4 (0.4) | 0.4 (0.4) | 13% |
Nasal symptoms | 2.4 (0.2) | 0.8 (0.3) | 32% | 3.2 (0.2) | 0.5 (0.2) | 15% |
Eye symptoms | 1.8 (0.2) | 0.6 (0.2) | 31% | 2.6 (0.3) | 0.7 (0.3) | 25% |
Emotional factors | 1.9 (0.3) | 0.9 (0.3) | 47% | 3.0 (0.2) | 0.8 (0.2) | 27% |
Combined domains | 2.3 (0.2) | 0.9 (0.2) | 41% | 3.2 (0.2) | 0.7 (0.2) | 20% |
Abbreviation: N, number of patients.
Lower RQLQ scores indicate improvement in quality of life.
For each domain, baseline differences between groups were significantly different, except for the Sleep domain. Mean changes from baseline to end of study of each domain were not significantly different. Percent relative change of each domain was larger for ICX72, compared with placebo.